It's substantial., Investing in a Biotech with only 1 product and no revenues.
It's substantial. Investing in a Biotech with only 1 product and no revenues WAS a risky investment.
A 9 year trial is expensive.
The trial is nearing its completion and it's financial history is irrelevant. Now is the time!
CEL-SCI had a dubious past. There is no way around that.
Many offerings. 3 Reverse Splits. We know!
HAD is the key word.
BUT IT'S THE PAST, MAN!
It's now 2020 and the trial is about to end.
The SEC, the FDA and the IDMC have all poked around and reviewed everything! They know EXACTLY what happened over the years. All 3 agencies said "Nothing to see here and to continue on!"
There simply isn't anything nefarious.
Rarely do the Shorts attack the Science behind Multikine. Why? Because they can't! Its always things unrelated to the trial!
Multikine, CEL-SCI's lead investigational immunotherapy, is an immunotherapeutic agent that is being developed as a potential first-line neoadjuvant therapy in patients with squamous cell carcinoma of the head and neck, and potentially, as a treatment for cervical dysplasia or peri-anal warts in HIV/HPV co-infected patients. If it were to be approved for use following completion of CEL-SCI's clinical development program, Multikine would be a different kind of therapy in the fight against cancer; one that appears to have the potential to work with the body's natural immune system in the fight against tumors. Multikine may also have the potential to be a first in a new class of cancer immunotherapy drugs. It is the first investigational combination immunotherapy thought to have both passive and active immune properties and has displayed the following characteristics in studies to date:
Copyright © 2020 MG-Short - All Rights Reserved.
Visit KillCVMShorts.com for more info